Purchase this article with an account.
Wataru Kikushima, Yoichi Sakurada, Hiroyuki Iijima; Factors predictive of visual outcome after intravitreal aflibercept injection treatment for typical neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4609.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the factors associated with visual outcomes after intravitreal aflibercept injection (IAI) for typical neovascular AMD.
We retrospectively studied the visual changes in 46 eyes of 42 patients with typical neovascular AMD, who had been initially treated with three monthly IAI followed by as-needed IAI.
Mean best-corrected visual acuity (BCVA) improved during the 6-month follow-up period in 36 eyes of 33 patients without reticular pseudodrusen (RPD) in both eyes, whereas it deteriorated in 10 eyes of 9 patients with RPD in either eye. Multiple regression analysis revealed that visual gain at 6 months after the first IAI positively correlated with worse baseline BCVA, thicker baseline subfoveal choroidal thickness, and shorter length of the greatest linear dimension of the baseline lesion (p<0.001, p=0.028, and p=0.045, respectively) but not with absence of RPD (p=0.28). Subfoveal choroidal thickness was significantly thinner in eyes with RPD compared with that in eyes without RPD (p=0.008).
Visual gain after IAI in eyes with typical neovascular AMD appears to be limited in patients with RPD, which may reflect the poor visual outcome after IAI in eyes with a thinner subfoveal choroid that is seen predominately in patients with RPD.
This PDF is available to Subscribers Only